Tresprostinil Products(Remodulin,generic treprostinil)

Remodulin (treprostinil) is covered for FDA‑approved PAH (WHO Group I, including transition from epoprostenol) and compendial off‑label use for CTEPH, and is not covered for indications outside these criteria. Coverage requires right‑heart catheterization confirmation, prescribing or consult by a pulmonologist/cardiologist, initial NYHA class III–IV (class II allowed only with prior oral or inhaled/parenteral therapy), continuous subcutaneous (preferred) or IV infusion only with dosing limits (PAH ≤100 ng/kg/min; CTEPH ≤50 ng/kg/min), 12‑month approvals with renewals requiring documented clinical benefit, and up to a 30‑day short supply if documentation is incomplete.

"Treatment of pulmonary arterial hypertension (PAH) World Health Organization (WHO) Group I to diminish symptoms associated with exercise."

Sign up to see full coverage criteria, indications, and limitations.